Skip to content. | Skip to navigation


Personal tools

Marcel Bally, Ph.D

Peer-Reviewed Papers

Peer-Reviewed PapersNon Peer-Reviewed Papers | Review Papers | Books (and Chapters)

        2011     

  1. Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G and Bally MB (2011).   “Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation Design, pharmacokinetics and efficacy”  J Control Release. 2011 Mar 10;150(2):212-9. Epub 2010 Nov 19
  2. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT and Dedhar S (2011)  “Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors” Cancer Research 2011 May 1;71(9):3364-3376. [Epub 2011 Mar 17]
  3. Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strutt D, Osooly M, Masin D and Bally M (2011) "Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267" Cancer Biol Ther. 2011 May 1:11(9):826-38. [Epub 2011 May 1]
  4. Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D,  Bally MB and Yapp DT (2011) “Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore C), doxorubicin (Caelyx) or vincristine”  BMC Cancer, 2011 Apr 8;11:124. (2011).


    2010 

     

  5. Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, Brief E and Wasan EK (2010).  “The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo”  J Pharm Sci. 2010 May;99(5):2295-308. [Epub 2009 Nov 09]
  6. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J Pharm Sci. 2010, Jun;99(6):2839-53. [Epub 2009 Nov 23]
  7. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 
  8. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]
  9. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)
  10. Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE and Bally MB. (2010)  “Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1”  Oncogene. 2010 Dec 2;29(48):6343-56. [Epub 2010 Sep 13]
  11. Patankar N, Anantha M, Ramsay E, Waterhouse D and Bally M (2010).   “The role of the transition metal copper and the ionophore A23187 in the development of irinophore CTM”  Pharm Res. 2011 Apr;28(4):848-57. [Epub 2010 Dec 23]



    2009 
  12. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009

  13. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).

  14. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).

  15. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008 

  16. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008)

  17. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008)

  18. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008)

  19. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008)

  20. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008)

  21. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  22. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007 

  23. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  24. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  25. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  26. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  27. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  28. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  29. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  30. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  31. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  32. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  33. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  34. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  35. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  36. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  37. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  38. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  39. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  40. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  41. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  42. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  43. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  44. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  45. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  46. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  47. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  48. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  49. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  50. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  51. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  52. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  53. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  54. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  55. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  56. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  57. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  58. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  59. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  60. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  61. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  62. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  63. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  64. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  65. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  66. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  67. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  68. Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  69. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  70. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  71. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  72. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  73. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  74. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  75. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  76. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  77. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  78. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  79. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  80. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  81. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  82. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  83. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  84. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  85. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  86. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  87. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  88. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  89. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  90. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  91. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  92. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  93. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  94. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  95. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  96. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  97. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  98. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  99. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  100. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  101. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  102. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  103. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  104. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  105. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  106. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  107. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  108. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  109. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  110. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  111. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  112. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  113. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  114. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  115. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  116. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  117. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  118. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  119. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  120. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  121. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  122. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  123. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  124. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  125. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  126. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  127. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  128. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  129. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  130. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  131. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  132. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  133. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  134. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  135. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  136. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  137. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  138. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  139. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  140. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  141. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  142. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  143. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  144. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  145. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  146. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  147. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  148. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  149. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  150. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  151. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  152. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  153. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  154. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  155. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  156. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  157. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  158. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  159. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  160. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  161. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  162. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  163. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  164. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  165. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  166. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  167. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  168. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  169. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  170. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  171. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  172. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  173. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  174. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  175. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  176. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  177. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  178. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  179. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  180. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  181. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  182.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  183. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  184. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  185. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  186. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  187. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]
  188. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  189. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  190. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)




    2009
     
  191. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009
  192. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).
  193. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).
  194. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008

  195. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).

  196. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008).

  197. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008).

  198. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008).

  199. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008).

  200. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  201. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007

  202. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  203. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  204. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  205. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  206. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  207. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  208. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  209. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  210. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  211. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  212. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  213. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  214. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  215. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  216. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  217. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  218. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  219. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  220. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  221. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  222. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  223. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  224. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  225. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  226. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  227. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  228. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  229. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  230. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  231. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  232. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  233. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  234. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  235. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  236. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  237. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  238. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  239. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  240. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  241. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  242. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  243. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  244. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  245. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  246. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  247.  Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  248. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  249. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  250. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  251. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  252. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  253. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  254. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  255. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  256. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  257. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  258. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  259. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  260. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  261. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  262. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  263. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  264. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  265. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  266. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  267. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  268. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  269. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  270. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  271. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  272. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  273. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  274. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  275. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  276. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  277. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  278. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  279. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  280. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  281. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  282. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  283. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  284. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  285. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  286. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  287. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  288. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  289. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  290. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  291. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  292. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  293. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  294. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  295. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  296. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  297. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  298. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  299. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  300. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  301. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  302. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  303. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  304. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  305. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  306. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  307. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  308. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  309. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  310. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  311. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  312. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  313. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  314. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  315. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  316. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  317. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  318. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  319. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  320. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  321. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  322. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  323. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  324. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  325. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  326. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  327. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  328. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  329. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  330. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  331. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  332. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  333. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  334. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  335. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  336. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  337. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  338. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  339. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  340. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  341. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  342. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  343. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  344. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  345. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  346. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  347. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  348. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  349. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  350. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  351. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  352. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  353. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  354. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  355. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  356. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  357. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  358. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  359. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  360. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  361.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  362. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  363. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  364. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  365. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  366. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]

  367. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  368. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  369. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)

  1. Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G and Bally MB (2011).   “Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation Design, pharmacokinetics and efficacy”  J Control Release. 2011 Mar 10;150(2):212-9. Epub 2010 Nov 19
  2. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT and Dedhar S (2011)  “Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors” Cancer Research 2011 May 1;71(9):3364-3376. [Epub 2011 Mar 17]
  3. Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strutt D, Osooly M, Masin D and Bally M (2011) "Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267" Cancer Biol Ther. 2011 May 1:11(9):826-38. [Epub 2011 May 1]
  4. Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D,  Bally MB and Yapp DT (2011) “Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore C), doxorubicin (Caelyx) or vincristine”  BMC Cancer, 2011 Apr 8;11:124. (2011).


    2010 

     

  5. Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, Brief E and Wasan EK (2010).  “The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo”  J Pharm Sci. 2010 May;99(5):2295-308. [Epub 2009 Nov 09]
  6. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J Pharm Sci. 2010, Jun;99(6):2839-53. [Epub 2009 Nov 23]
  7. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 
  8. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]
  9. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)
  10. Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE and Bally MB. (2010)  “Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1”  Oncogene. 2010 Dec 2;29(48):6343-56. [Epub 2010 Sep 13]
  11. Patankar N, Anantha M, Ramsay E, Waterhouse D and Bally M (2010).   “The role of the transition metal copper and the ionophore A23187 in the development of irinophore CTM”  Pharm Res. 2011 Apr;28(4):848-57. [Epub 2010 Dec 23]



    2009 
  12. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009

  13. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).

  14. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).

  15. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008 

  16. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008)

  17. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008)

  18. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008)

  19. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008)

  20. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008)

  21. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  22. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007 

  23. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  24. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  25. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  26. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  27. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  28. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  29. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  30. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  31. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  32. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  33. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  34. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  35. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  36. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  37. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  38. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  39. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  40. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  41. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  42. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  43. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  44. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  45. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  46. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  47. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  48. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  49. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  50. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  51. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  52. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  53. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  54. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  55. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  56. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  57. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  58. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  59. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  60. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  61. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  62. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  63. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  64. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  65. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  66. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  67. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  68. Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  69. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  70. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  71. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  72. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  73. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  74. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  75. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  76. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  77. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  78. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  79. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  80. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  81. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  82. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  83. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  84. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  85. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  86. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  87. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  88. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  89. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  90. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  91. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  92. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  93. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  94. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  95. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  96. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  97. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  98. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  99. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  100. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  101. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  102. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  103. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  104. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  105. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  106. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  107. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  108. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  109. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  110. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  111. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  112. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  113. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  114. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  115. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  116. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  117. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  118. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  119. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  120. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  121. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  122. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  123. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  124. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  125. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  126. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  127. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  128. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  129. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  130. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  131. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  132. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  133. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  134. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  135. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  136. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  137. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  138. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  139. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  140. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  141. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  142. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  143. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  144. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  145. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  146. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  147. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  148. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  149. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  150. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  151. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  152. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  153. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  154. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  155. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  156. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  157. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  158. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  159. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  160. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  161. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  162. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  163. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  164. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  165. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  166. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  167. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  168. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  169. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  170. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  171. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  172. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  173. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  174. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  175. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  176. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  177. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  178. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  179. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  180. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  181. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  182.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  183. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  184. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  185. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  186. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  187. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]
  188. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  189. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  190. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)




    2009
     
  191. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009
  192. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).
  193. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).
  194. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008

  195. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).

  196. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008).

  197. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008).

  198. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008).

  199. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008).

  200. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  201. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007

  202. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  203. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  204. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  205. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  206. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  207. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  208. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  209. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  210. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  211. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  212. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  213. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  214. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  215. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  216. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  217. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  218. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  219. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  220. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  221. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  222. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  223. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  224. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  225. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  226. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  227. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  228. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  229. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  230. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  231. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  232. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  233. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  234. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  235. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  236. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  237. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  238. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  239. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  240. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  241. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  242. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  243. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  244. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  245. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  246. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  247.  Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  248. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  249. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  250. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  251. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  252. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  253. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  254. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  255. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  256. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  257. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  258. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  259. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  260. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  261. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  262. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  263. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  264. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  265. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  266. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  267. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  268. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  269. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  270. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  271. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  272. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  273. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  274. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  275. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  276. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  277. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  278. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  279. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  280. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  281. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  282. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  283. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  284. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  285. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  286. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  287. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  288. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  289. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  290. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  291. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  292. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  293. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  294. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  295. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  296. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  297. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  298. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  299. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  300. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  301. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  302. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  303. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  304. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  305. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  306. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  307. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  308. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  309. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  310. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  311. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  312. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  313. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  314. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  315. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  316. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  317. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  318. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  319. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  320. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  321. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  322. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  323. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  324. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  325. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  326. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  327. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  328. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  329. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  330. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  331. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  332. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  333. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  334. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  335. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  336. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  337. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  338. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  339. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  340. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  341. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  342. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  343. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  344. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  345. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  346. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  347. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  348. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  349. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  350. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  351. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  352. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  353. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  354. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  355. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  356. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  357. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  358. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  359. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  360. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  361.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  362. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  363. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  364. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  365. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  366. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]

  367. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  368. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  369. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)

 

  1. Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, Karlsson G and Bally MB (2011).   “Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation Design, pharmacokinetics and efficacy”  J Control Release. 2011 Mar 10;150(2):212-9. Epub 2010 Nov 19
  2. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT and Dedhar S (2011)  “Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors” Cancer Research 2011 May 1;71(9):3364-3376. [Epub 2011 Mar 17]
  3. Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strutt D, Osooly M, Masin D and Bally M (2011) "Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267" Cancer Biol Ther. 2011 May 1:11(9):826-38. [Epub 2011 May 1]
  4. Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D,  Bally MB and Yapp DT (2011) “Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (irinophore C), doxorubicin (Caelyx) or vincristine”  BMC Cancer, 2011 Apr 8;11:124.
  5. 2010
  6. Banno B, Ickenstein LM, Chiu GN, Bally MB, Thewalt J, Brief E and Wasan EK (2010).  “The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo”  J Pharm Sci. 2010 May;99(5):2295-308. [Epub 2009 Nov 09]
  7. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman I, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J Pharm Sci. 2010, Jun;99(6):2839-53. [Epub 2009 Nov 23]
  8. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 
  9. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]
  10. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)
  11. Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE and Bally MB. (2010)  “Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1”  Oncogene. 2010 Dec 2;29(48):6343-56. [Epub 2010 Sep 13]
  12. Patankar N, Anantha M, Ramsay E, Waterhouse D and Bally M (2010).   “The role of the transition metal copper and the ionophore A23187 in the development of irinophore CTM”  Pharm Res. 2011 Apr;28(4):848-57. [Epub 2010 Dec 23]



    2009 
  13. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009

  14. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).

  15. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).

  16. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008 

  17. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008)

  18. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008)

  19. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008)

  20. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008)

  21. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008)

  22. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  23. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007 

  24. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  25. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  26. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  27. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  28. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  29. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  30. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  31. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  32. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  33. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  34. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  35. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  36. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  37. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  38. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  39. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  40. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  41. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  42. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  43. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  44. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  45. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  46. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  47. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  48. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  49. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  50. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  51. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  52. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  53. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  54. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  55. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  56. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  57. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  58. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  59. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  60. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  61. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  62. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  63. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  64. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  65. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  66. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  67. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  68. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  69. Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  70. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  71. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  72. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  73. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  74. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  75. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  76. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  77. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  78. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  79. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  80. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  81. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  82. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  83. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  84. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  85. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  86. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  87. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  88. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  89. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  90. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  91. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  92. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  93. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  94. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  95. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  96. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  97. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  98. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  99. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  100. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  101. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  102. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  103. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  104. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  105. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  106. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  107. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  108. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  109. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  110. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  111. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  112. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  113. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  114. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  115. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  116. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  117. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  118. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  119. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  120. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  121. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  122. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  123. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  124. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  125. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  126. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  127. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  128. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  129. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  130. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  131. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  132. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  133. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  134. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  135. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  136. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  137. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  138. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  139. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  140. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  141. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  142. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  143. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  144. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  145. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  146. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  147. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  148. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  149. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  150. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  151. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  152. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  153. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  154. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  155. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  156. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  157. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  158. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  159. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  160. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  161. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  162. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  163. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  164. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  165. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  166. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  167. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  168. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  169. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  170. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  171. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  172. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  173. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  174. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  175. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  176. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  177. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  178. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  179. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  180. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  181. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  182. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  183.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  184. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  185. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  186. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  187. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  188. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]
  189. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  190. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  191. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)




    2009
     
  192. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E and Wasan E (2009).  “The Functional Roles of Poly(ethylene glycol)-Lipid and Lysolipid in the Drug Retention and Release from Lysolipid-Containing Thermosensitive Liposomes In Vitro and In Vivo”  Journal of Pharma Sciences 2009
  193. Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res. 11(3):R25. (2009).
  194. Musende AG, Eberding A, Wood C, Adomat H, Fazli L, Hurtado-Coll A, Jia W, Bally MB, Guns ET. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy. Cancer Chemother Pharmacol. 2009 Mar 20. (2009).
  195. Verreault M, Bally MB. siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing. Oligonucleotides. 19(2):129-40. (2009).


    2008

  196. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT. Irinophore CTM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).

  197. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB. Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2008).

  198. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell E, Bally MB, Foster L and Dedhar S . Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylatin and Cancer Cell Survival Cancer Res 2008;68(6):1618-24 (2008).

  199. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB and Gorski SM . Macroautophagy Inhibition Sensitizes Tamoxifen-Resistant Breast Cancer Cells and Enhances Mitochondrial Depolarization Breast Cancer Res Treat. 2008 Dec;112(3):389-403. Epub 2008 Jan (2008).

  200. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D and Bally MB. Irinophore CTM : A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy Against a Panel of Human Xenograft Tumors Clin Cancer Res. 2008;14(4):1208-17 (2008).

  201. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, Wilson IM, Masin D, Gascoyne RD, Bally MB and Klasa RJ . Silencing Bcl-2 in Models of Mantle Cell Lymphoma Correlates with a Loss in Cyclin D1a Expression but not Cyuclin D1b and is Associated with Decreases in NFkappaB, p53, bax and p27 Levels Molecular Cancer Therapy 2008 Apr;7(4):749-58 (2008).

  202. Woo J, Chiu GN, Karlsson G, Wasan E, Ickenstein L, Edwards K, Bally MB. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm. 349(1-2):38-46. Epub 2007 Jul 24. (2008).


    2007

  203. Chiu GN, Edwards LA, Kapanen AI, Malinen MM, Dragowska WH, Warburton C, Chikh GG, Fang KY, Tan S, Sy J, Tucker C, Waterhouse DN, Klasa R, Bally MB. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs. Mol Cancer Ther. 6(3):844-55. Epub 2007 Mar 5. (2007).

  204. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 1768(6):1367-77. Epub 2007 Jan 3. (2007).

  205. Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB. Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res Treat. . (2007).

  206. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 99(1):53-63. (2007).

  207. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D and Bally MB. A Novel Liposomal Irinotecan Formulation with Significant Anti-tumor Activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm 2008 Mar;68(3):607-17. Epub 2007 Sept 2. (2007).

  208. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768(3):678-87. Epub 2006 Dec 6. (2007).

  209. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally MB, Yapp D and Dunn SE . The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. (2007).

  210. Webb MS, Boman N, Masin D, Yapp D, Ramsay E, Chiu GNC, Cullis PR, and Bally MB . A Cationic Liposomal Vincristine Formulation with Improved Vincristine Retention, Extended Circulation Lifetime and Increased Anti-Tumor Activity Letters in Drug Design and Discovery September 2007;4(6):426-433. (2007).

  211. Webb MS, Johnstone S, Morris TJ, Kennedy A, Gallagher R, Harasym N, Harasym T, Shew CR, Tardi P, Dragowska WH, Mayer LD, Bally MB. In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm. 65(3):289-99. Epub 2006 Oct 17. (2007).

  212. Webb MS, Rebstein P, Lamson W and Bally MB . Liposomal Drug Delivery: Recent Patents and Emerging Opportunities Recent Patents on Drug Delivery and Formulation 2007, 1(3) (2007).

  213. Zastre J, Anantha M, Ramsay E, Bally MB. Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol. 60(1):91-102. Epub 2006 Sep 29. (2007).


    2006

  214. Chiu GNC, Harasym TO, Tardi PG, Bally MB and Waterhouse DN. Optimization and Therapeutic Activity of Liposome-Conjugated Monoclonal Antibodies Against the ErbB Family of Receptor Tyrosin Kinases: First Step in the Development of Therapeutic Antibody/Liposomal anticancer Drug Combinations Letters in Drug Design and Discovery (2006).

  215. Cogswell S, Berger S, Waterhouse D, Bally MB, Wasan EK. A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model. Pharm Res. 23(11):2575-85. Epub 2006 Sep 13. (2006).

  216. Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB. Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther. 5(3):645-54. (2006).

  217. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 5(7):1854-63. (2006).

  218. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, Bally MB. Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23(12):2799-808. Epub 2006 Oct 25. (2006).

  219. Taggar AS, Alnajim J, Anantha M, Thomas A, Webb M, Ramsay E, Bally MB. Copper-topotecan complexation mediates drug accumulation into liposomes. J Control Release. 114(1):78-88. Epub 2006 Jun 2. (2006)

  220. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res. 66(1):393-403. (2006).

  221. Tucker CA, Bebb G, Klasa RJ, Chhanabhai M, Lestou V, Horsman DE, Gascoyne RD, Wiestner A, Masin D, Bally MB, Williams ME. Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leuk Res. 30(4):449-57. Epub 2005 Sep 23. (2006).

  222. Verreault M, Webb MS, Ramsay EC, Bally MB. Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems. Curr Gene Ther. 6(4):505-33. (2006).

  223. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 56(5):1011-8. (2006).

  224. Waterhouse DN, Gelmon KA, Klasa R, Chi K, Huntsman D, Ramsay E, Wasan E, Edwards L, Tucker C, Zastre J, Wang YZ, Yapp D, Dragowska W, Dunn S, Dedhar S, Bally MB. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets. 6(6):455-89. (2006).


    2005

  225. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 391:71-97. (2005).

  226. Chiu GN, Abraham SA, Ickenstein LM, Ng R, Karlsson G, Edwards K, Wasan EK, Bally MB. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release. 104(2):271-88. Epub 2005 Apr 13. (2005).

  227. Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 105(1-2):89-105. (2005).

  228. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene. 24(22):3596-605. (2005).

  229. Edwards LA, Thiessen B, Dragowska WH, Daynard T, Bally MB, Dedhar S. Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene . (2005).

  230. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005).

  231. Waterhouse DN, Denyssevych T, Hudon N, Chia S, Gelmon KA, Bally MB. Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels. Pharm Res. 22(6):915-22. Epub 2005 Jun 8. (2005).


    2004

  232. Abraham SA, Edwards K, Karlsson G, Hudon N, Mayer LD, Bally MB. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes. J Control Release 96(3):449-61. (2004).

  233. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).

  234. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C, Bally MB. pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol. Biochim Biophys Acta 1661(1):47-60. (2004).

  235. Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization. Mol Cancer Res 2(11):606-19. (2004).

  236. Hu Y, Bebb G, Tan S, Ng R, Yan H, Sartor JR, Mayer LD, Bally MB. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 10(22):7662-70. (2004).

  237. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally MB. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).

  238. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, Bally MB. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10(19):6638-49. (2004).

  239. Schutze-Redelmeier MP, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine 22(15-16):1985-91. (2004).

  240. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery. Magn Reson Med 51(6):1153-62. (2004).

  241. Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction. Clin Cancer Res 10(7):2512-24. (2004).

  242. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8 (2004).


    2003

  243. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).

  244. Hu Y, Bally MB, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).

  245. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21(23):3319-29. (2003).

  246. Waterhouse DN, Gelmon KA, Masin D, Bally MB. Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model. J Exp Ther Oncol 3(5):261-71. (2003).

  247. Wong FM, Harvie P, Zhang YP, Ramsay EC, Bally MB. Phosphatidylethanolamine mediated destabilization of lipid-based pDNA delivery systems. Int J Pharm 255(1-2):117-27. (2003).


    2002

  248.  Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally MB. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).

  249. C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22(2):225-50. (2002).

  250. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB. Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1):204-12. (2002).

  251. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).

  252. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).

  253. Edwards LA, Woo J, Huxam LA, Verreault M, Chiu G, Rajput A, Kyle AH, Karle J, Dragowska WH, Yapp D, Yan H, Minchinton AK, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S and Bally MB . Suppression of VEGF Secretion and Changes in Glioblastoma Mmultiforme Microenvironment by Inhibition of Integrin-Linked Kinase (ILK) Mol Cancer Ther 2008 Jan;7(1):59-70 (2002).

  254. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).

  255. Hu Q, Bally MB, Madden TD. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system. Nucleic Acids Res 30(16):3632-41. (2002).

  256. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).

  257. Wasan EK, Waterhouse D, Sivak O, Bally MB, Klasa RJ, Wasan KM. Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241(1):57-64. (2002).

  258. Wong FMP, Macadam SA, Kim A, Oja C, Ramsay EC and Bally MB. A Lipid-Based Delivery System for Antisense Oligonucleotides Derived from a Hydrophobic Complex. J. of Drug Targeting 10(8):615-623 (2002).


    2001

  259. Chikh G, Bally MB, Schutze-Redelmeier MP. Characterization of hybrid CTL epitope delivery systems consisting of the Antennapedia homeodomain peptide vector formulated in liposomes. J Immunol Methods 254(1-2):119-35. (2001).

  260. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol 167(11):6462-70. (2001).

  261. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).

  262. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally MB, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).

  263. Hu Q, Shew CR, Bally MB, Madden TD. Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects. Biochim Biophys Acta 1514(1):1-13. (2001).

  264. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).

  265. Li WM, Bally MB, Schutze-Redelmeier MP. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes. Vaccine 20(1-2):148-57. (2001).

  266. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).

  267. Waterhouse D N, Tardi P G, Mayer L D, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).

  268. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).

  269. Wong M, Kong S, Dragowska WH, Bally MB. Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes. Biochim Biophys Acta 1527(1-2):61-72. (2001).


    2000

  270. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (2000).

  271. Harvie P, Wong FM, Bally MB. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89(5):652-63. (2000).

  272. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).

  273. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6(6):2492-500. (2000).

  274. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-45. (2000).

  275. Lim HJ, Parr MJ, Masin D, McIntosh NL, Madden TD, Zhang G, Johnstone S, Bally MB. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 6(11):4449-60. (2000).

  276. Mayer LD, Krishna R, Webb M and Bally MB. Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).

  277. Saxon D, Chia SK and Bally MB . Drug Combinations for Therapy of Aggressive Breast Cancer: Antisense Oligonucleotides Against HER-2/NEU Biological Therapy of Breast Cancer, 1(3):7-11. (2000).

  278. Tardi P, Choice E, Masin D, Redelmeier T, Bally MB, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 60(13):3389-93. (2000).


    1999

  279. Adlakha-Hutcheon G, Bally MB, Shew CR, Madden TD. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17(8):775-9. (1999).

  280. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, Reimer DL. Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38(3):291-315. (1999).

  281. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).

  282. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).

  283. Reimer DL, Kong S, Monck M, Wyles J, Tam P, Wasan EK, Bally MB. Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J Pharmacol Exp Ther 289(2):807-15. (1999).

  284. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).

  285. Wasan EK, Harvie P, Edwards K, Karlsson G, Bally MB. A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochim Biophys Acta 1461(1):27-46. (1999).

  286. Wong FM, Bally MB, Brooks DE. Electrostatically mediated interactions between cationic lipid-DNA particles and an anionic surface. Arch Biochem Biophys 366(1):31-9. (1999).


    1998

  287. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).

  288. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).

  289. Harvie P, Wong FM, Bally MB. Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J 75(2):1040-51. (1998).

  290. Tardi P, Bally MB, Harasym TO. Clearance properties of liposomes involving conjugated proteins for targeting. Adv Drug Deliv Rev 32(1-2):99-118. (1998).

  291. Wasan EK, Fairchild A, Bally MB. Cationic liposome--plasmid DNA complexes used for gene transfer retain a significant trapped volume. J Pharm Sci 87(1):9-14. (1998).

  292. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).

  293. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).


    1997

  294. Bally MB, Ansell SM, Tardi PG and Harasym TO. Liposome Targeting Following Intravenous Administration: Defining Expectations and a Need for Improved Methodology J. Liposome Res. 7(4):331-361. (1997).

  295. Bally MB, Zhang Y-P, Wong FMP, Kong S, Wasan E and Reimer DL . Lipid/DNA Complexes as an Intermediate in the Preparation of Particles for Gene Transfer: An Alternative to Cationic Liposome/DNA Aggregates Advanced Drug Delivery Reviews, 24(2-3):275-290. (1997).

  296. Chang CW, Barber L, Ouyang C, Masin D, Bally MB, Madden TD. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 75(2):169-77. (1997).

  297. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).

  298. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).

  299. Harasym TO, Cullis PR, Bally MB. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother Pharmacol 40(4):309-17. (1997).

  300. Lim HJ, Masin D, Madden TD, Bally MB. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-73. (1997).

  301. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).

  302. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther 280(3):1319-27. (1997).

  303. Reimer DL, Bally MB and Singh SM . Human gene therapy: Principles and modern advances Biotechnology Ann. Rev., 1997, 3:59-110. (1997).

  304. Reimer DL, Kong S, Bally MB. Analysis of cationic liposome-mediated interactions of plasmid DNA with murine and human melanoma cells in vitro. J Biol Chem 272(31):19480-7. (1997).

  305. Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J Immunol Methods 210(2):137-48. (1997).

  306. Zhang YP, Reimer DL, Zhang G, Lee PH, Bally MB. Self-assembling DNA-lipid particles for gene transfer. Pharm Res 14(2):190-6. (1997).


    1996

  307. Boman NL, Tron VA, Bally MB, Cullis PR. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 37(4):351-5. (1996).

  308. Silver HKB, Klasa RJ and Bally MB . Genetic Allogenization of Malignant Melanoma Transfus. Sci., 17(1):169-174. (1996).

  309. Wasan EK, Reimer DL, Bally MB. Plasmid DNA is protected against ultrasonic cavitation-induced damage when complexed to cationic liposomes. J Pharm Sci 85(4):427-33. (1996).

  310. Wong FM, Reimer DL, Bally MB. Cationic lipid binding to DNA: characterization of complex formation. Biochemistry 35(18):5756-63. (1996).


    1995

  311. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposome Res., 5:523-541. (1995).

  312. Choice E, Masin D, Bally MB, Meloche M, Madden TD. Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution. Transplantation 60(9):1006-11. (1995).

  313. De Jong G, Gelmon K, Bally MB, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).

  314. Harasym TO, Tardi P, Longman SA, Ansell SM, Bally MB, Cullis PR, Choi LS. Poly(ethylene glycol)-modified phospholipids prevent aggregation during covalent conjugation of proteins to liposomes. Bioconjug Chem 6(2):187-94. (1995).

  315. Longman SA, Cullis PR and Bally MB . A Model Approach for Assessing Liposome Targeting in vivo Drug Delivery, 2:156-165. (1995).

  316. Longman SA, Cullis PR, Choi L, de Jong G, Bally MB. A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo. Cancer Chemother Pharmacol 36(2):91-101. (1995).

  317. Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB. Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes. J Pharmacol Exp Ther 275(3):1177-84. (1995).

  318. Mayer LD, Gelmon K, Cullis PR, Boman N, Webb MS, Embree L, Tolcher T and Bally MB. Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery System, Vol. 4, pp. 151-161, Biomedical Research Foundation, Tokyo. (1995).

  319. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).

  320. Redelmeier TE, Guillet J-G and Bally MB . High Affinity Targeting of Biotin Labeled Liposomes to Streptavidin Conjugated Ligands Drug Delivery. 2:98-109. (1995).

  321. Reimer DL, Zhang Y, Kong S, Wheeler JJ, Graham RW, Bally MB. Formation of novel hydrophobic complexes between cationic lipids and plasmid DNA. Biochemistry 34(39):12877-83. (1995).

  322. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).

  323. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).


    1994

  324. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).

  325. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).

  326. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).

  327. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Liposomal Doxorubicin Liposome Res., 4:529-553. (1994).

  328. Wheeler JJ, Wong KF, Ansell SM, Masin D, Bally MB. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83(11):1558-64. (1994).


    1993

  329. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).

  330. Parr MJ, Bally MB, Cullis PR. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Biochim Biophys Acta 1168(2):249-52. (1993).


    1991

  331. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).


    1990

  332. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).

  333. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).

  334. Loughrey HC, Bally MB, Reinish LW, Cullis PR. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb Haemost 64(1):172-6. (1990).

  335. Loughrey HC, Choi LS, Cullis PR, Bally MB. Optimized procedures for the coupling of proteins to liposomes. J Immunol Methods 132(1):25-35. (1990).

  336. Loughrey HC, Wong KF, Choi LS, Cullis PR, Bally MB. Protein-liposome conjugates with defined size distributions. Biochim Biophys Acta 1028(1):73-81. (1990).

  337. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).

  338. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 1:463-480. (1990).

  339. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).

  340. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).

  341. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).

  342. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).


    1989

  343. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).

  344. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ. Generation and Loading of Liposomal Systems for Drug Delivery Application Advanced Drug Delivery Review 3:267-282. (1989).

  345. Doerschuk CM, Gie RP, Bally MB, Cullis PR, Reinish LW. Platelet distribution in rabbits following infusion of liposomes. Thromb Haemost 61(3):392-6. (1989).

  346. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).

  347. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).


    1988

  348. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).

  349. Reinish LW, Bally MB, Loughrey HC, Cullis PR. Interactions of liposomes and platelets. Thromb Haemost 60(3):518-23. (1988).


    1987

  350. Loughrey H, Bally MB, Cullis PR. A non-covalent method of attaching antibodies to liposomes. Biochim Biophys Acta 901(1):157-60. (1987).


    1986

  351. Hope MJ, Bally MB, Mayer LD, Janoff AS and Cullis PR. Generation of Multilamellar and Unilamellar Phospholipid Vesicles Chem. Phys. Lipids 40:89-108. (1986).

  352. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).

  353. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).


    1985

  354. Bally MB, Hope MJ, van Echteld CJA and Cullis PR . Uptake of Safranine and Other Lipophilic Cations into Vesicles in Response to a Membrane Potential Biochim. Biophys. Acta 812:66-76. (1985).

  355. Hope MJ, Bally MB, Webb G and Cullis PR . Production of Large Unilamellar Vesicles by a Rapid Extrusion Procedure: Characterization of Size, Trapped Volume and Ability to Maintain a Membrane Potential Biochim. Biophys. Acta 812:55-65. (1985).

  356. Madden TD, Bally MB, Hope MJ, Cullis PR, Schieren HP, Janoff AS. Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents. Biochim Biophys Acta 817(1):67-74. (1985).

  357. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).

  358. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).

  359. Shertzer HG, Bally MB, Opheim DJ. Inhibition of alveolar macrophage killing by di(2-ethylhexyl)phthalate. Arch Environ Contam Toxicol 14(5):605-8. (1985).

  360. Thomas P, Bally MB and Neff JM . Influence of Some Environmental Variables on the Ascorbic Acid Status of Mullet (Mugil Cephalus Linn.) Tissues II. Seasonal Fluctuations and Biosynthetic Ability J. Fish Biol. 27:47-57. (1985).


    1984

  361. Tilcock CP, Bally MB, Farren SB, Cullis PR, Gruner SM. Cation-dependent segregation phenomena and phase behavior in model membrane systems containing phosphatidylserine: influence of cholesterol and acyl chain composition. Biochemistry 23(12):2696-703. (1984).


    1983

  362.  Bally MB, Tilcock CP, Hope MJ, Cullis PR. Polymorphism of phosphatidylethanolamine-phosphatidylserine model systems: influence of cholesterol and Mg2+ on Ca2+-triggered bilayer to hexagonal (HII) transitions. Can J Biochem Cell Biol 61(6):346-52. (1983).

  363. Carr RS, Bally MB, Thomas P, Neff JM. Comparison of methods for determination of ascorbic acid in animal tissues. Anal Chem 55(8):1229-32. (1983).


    1982

  364. Thomas P, Bally MB and Neff JM . Ascorbic Acid Status of Mullet Exposed to Cadmium J. Fish Biology 20:183-186. (1982).

  365. Tilcock CP, Bally MB, Farren SB, Cullis PR. Influence of cholesterol on the structural preferences of dioleoylphosphatidylethanolamine-dioleoylphosphatidylcholine systems: a phosphorus-31 and deuterium nuclear magnetic resonance study. Biochemistry 21(19):4596-601. (1982).


    1980

  366. Bally MB, Opheim DJ, Shertzer HG. Di-(2-ethylhexyl) phthalate enhances the release of lysosomal enzymes from alveolar macrophages during phagocytosis. Toxicology 18(1):49-60. (1980).

  367. Ho EA, Ramsay E, Ginj M, Anantha M, Bregman S, Sy J, Woo J, Osooly-Talesh M, Yapp DT, and Bally MB (2010)  “Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties” J of Pharma Sciences 2010, Jan 20  [Epub ahead of print]

  368. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Lawrence Amankwa, Waterhouse D, Masin D, Webb M, Harasym N, Heller L, Bally MB, Ciufolini MA, Cullis PR, Maurer N: “Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles” J Control Release 2010 Jun 15; 144(3):332-40.  [Epub 2010 Mar 2] 

  369. Musende AG, Eberding A, Jia W, Ramsay E, Bally MB and Guns ET. (2010) “Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer”  Prostate 2010 Apr 28 [Epub ahead of print]

  370. Weiss A, Preston TC,  Popov J, Li Q, Wu S, Chou KC, Burt HM, Bally MB and Signorell R. “Selective Recognition of Rituximab-Functionalized Gold Nanoparticles by Lymphoma Cells Studied with 3D Imaging”  J. Phys. Chem.  (In Press)

 

Non Peer-Reviewed Papers

 

        2009

  1. Bally MB, Tardi P, Harasym T, Harasym N, Swenson C, Janoff A and Mayer LD. "Spotlight Celator Technologies" Controlled Release Society Newsletter, vol.21, number 2, 2004 (2004).

 

Review Papers

 
 

        2005

  1. Ramsay EC, Dos Santos N, Dragowska WH, Laskin JJ, Bally MB. The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations. Curr Drug Deliv. 2(4):341-51. (2005). 


    2004

  2. Edwards LA, Shabbits JA, Bally M, Dedhar S. Integrin-linked kinase (ILK) in combination molecular targeting. Cancer Treat Res 119:59-75. (2004).

 

Books (and Chapters)

 

        2008

  1. Waterhouse DN, Kalra J, Verreault M, Ramsay E, Dragowska W, Yapp D, Webb M, Chiu G and Bally MB . Nanotechnology as an Enabling Approach to the Development of Fixed-Dose Combination Products for Treating Cancer In: Handbook of Particulate Drug Delivery, Vol.2: Applications, pp.11-39 (M.N.V. Ravi Kumar, Ed), American Scientific Publishers (2008).

     

    2006

  2. Harasym TO, Tardi PG, Johnstone SA, Mayer LD, Bally MB and Janoff AS. Fixed Drug Ratio Liposome Formulations of Combination Cancer Therapeutics Liposome Technology Third Edition, Vol. III, Interactions of Liposomes with the Biological Milieu, pp.25-48 (G. Gregoriadis, Ed), Informa Healthcare USA, Inc. (2006).

     

    2005

  3. Abraham SA, Waterhouse DN, Mayer L, Cullis P, Madden T and Bally MB. Liposomal Formulations of Doxorubicin In: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.71-97 (N. Duzgunes, Ed), Elsevier Academic Press (2005).

  4. Waterhouse DN, Bally MB, Mayer LD, Madden TD, Cullis PR and Webb MS. Preparation, Characterization and Biological Analysis of Liposomal Formulations of Vincristine n: Methods in Enzymology, Vol.391, Liposomes, Part E, pp.40-57 (N. Duzgunes, Ed), Elsevier Academic Press (2005).

     

    2001

  5. Mayer LD, Krishna R and Bally, MB . Liposomes for Cancer Therapy Applications In: Polymeric Biomaterials, 2nd Edition (S. Dumitriu, ed.) Marcel Dekker (New York, NY), 823-841. (2001).

  6. Tardi P, Ickenstein L, Bally MB and Mayer LD . The Development of Liposomes for Enhanced Delivery of Chemotherpeutics to Tumors In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy, pp. 119-135 (M. Page, Ed), Humana Press Inc., Totowa, NJ. (2001).

     

    2000

  7. Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB and Cullis PR. Antibody Conjugation Methods for Active Targeting of Lipsomes In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 51-68 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ. (2000).

  8. Wasan EK, Reimer DL, Harvie P, Kong S, Wong FMP and Bally MB . Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems In: Methods in Molecular Medicine, Vol. 25: Drug Targeting: Strategies, Principles, and Applications, pp. 255-304 (G.E. Francis and C. Delgado, Ed.), Humana Press Inc., Totowa, NJ. (2000).

     

    1998

  9. Mayer LD, Cullis PR and Bally MB . Designing Therapeutically Optimized Liposomal Anticancer Delivery Systems: Lessons from Conventional Liposomes In: Medical Applications of Liposomes, DD Lasic and D Papahadjopoulos, eds., Elsevier, N.Y., pp. 231-257. (1998).

     

    1997

  10. Boman NL, Cullis PR, Mayer LD, Bally MB and Webb MS . Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations In: Long Circulating Liposomes: Old Drugs, New Therapeutics, 29-49. (1997).

     

    1995

  11. Boman NL, Cullis PR, Bally MB and Mayer LD . Preclinical and Clinical Activity of Liposomal Doxorubicin In: Liposomes in Biomedical Applications, (PN Shek, Ed.), 85-103. (1995).

     

    1993

  12. Bally MB, Mayer LD, Hope MJ and Nayar R . Pharmacodynamics of Liposomal Drug Carriers: Methodological Considerations In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 27-42, CRC Press, Inc., Boca Raton, FL. (1993).

  13. Loughrey HC, Choi LS, Wong KF, Cullis PR and Bally MB . Preparation of Streptavidin Liposomes for use in Ligand Specific Targeting Applications In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 3, Pp. 163-178, CRC Press, Inc., Boca Raton, FL. (1993).

  14. Mayer LD, Bally MB, Madden TD and Cullis PR . Transmembrane pH Gradient Driven Drug Loading Procedure In: Liposome Technology: 2nd Edition, (G Gregoriadis, Ed.), Vol. 2, Pp. 27-44, CRC Press, Inc., Boca Raton, FL. (1993).

     

    1988

  15. Bally MB, Hope MJ, Mayer LD, Madden TD and Cullis PR . Novel Procedures for Generating and Loading Liposomal Systems In: Liposomes As Drug Carriers: Recent Trends and Progress, (G Gregoriadis, Ed.), John Wiley and Sons, New York, Pp. 841-853. (1988).

     

    1987

  16. Cullis PR, Hope MJ, Bally MB, Janoff AS, Madden TD and Mayer LD . Liposomes As Pharmaceuticals In: Liposomes, (M Ostro, Ed.), Marcel Dekker, New York, Pp. 39-72. (1987).

     

    1982

  17. Cullis PR, De Kruiff B, Hope MJ, Verkleij AJ, Nayar R, Farren SB, Tilcock CPS, Madden TD and Bally MB . Structural Properties of Lipids and Their Functional Roles in Biological Membranes In: Membrane Fluidity, Volume 2, (RC Aloia, Ed.), Academic Press, New York, Pp. 39-81. (1982).

     

     Back to Marcel Bally

         Back to Main Page